Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ATI-105 in Healthy Adults

NCT07869654 is registered in ClinicalTrials.gov with Adjuvia Therapeutics, Inc. as lead sponsor.

NCT NCT07869654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07869654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ATI-105 in Healthy Adults
Lead sponsor
Adjuvia Therapeutics, Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 26, 2026
Completion date
June 27, 2027
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiomyopathies, central nervous system diseases, friedreich ataxia, genetic disease, mitochondrial diseases, mitochondrial dysfunction, neuromuscular diseases